Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis

Oncogene

Volumn 25, Issue 24, 2006, Pages 3479-3488

  Veeck, J ^a   Niederacher, D ^b   An, H ^a,e   Klopocki, E ^c   Wiesmann, F ^a   Betz, B ^b   Galm, O ^a   Camara, O ^d   Durst M ^d   Kristiansen, G ^c   Huszka, C ^a   Knuchel R ^a   Dahl, E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Breast cancer; Epigenetics; Methylation; SFRP1; Tumour suppressor gene; Wnt pathway

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MEMBRANE PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; METHYLATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLYCOPROTEINS; HUMANS; MIDDLE AGED; WNT PROTEINS;

EID: 33745026527     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209386     Document Type: Article

References (40)

1. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA. (1999). J Biol Chem 274: 6180-6187.
2. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R et al. (1996). Nature 382: 638-642.
3. Brown AM. (2001). Breast Cancer Res 3: 351-355.
4. Cadigan KM, Nusse R. (1997). Genes Dev 11: 3286-3305.
5. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P et al. (2004). Cancer Res 64: 883-888.
6. Costa FF, Verbisck NV, Salim AC, Ierardi DF, Pires LC, Sasahara RM et al. (2004). Oncogene 23: 1481-1488.
7. Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R et al. (2005). J Pathol 205: 21-28.
8. Egger G, Liang G, Aparicio A, Jones PA. (2004). Nature 429: 457-463.
9. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B et al. (2002). J Natl Cancer Inst 94: 26-32.
10. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. (1999). Cancer Res 59: 793-797.
11. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC et al. (1997). Proc Natl Acad Sci USA 94: 6770-6775.
12. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F et al. (1998). Nat Med 4: 1329-1333.
13. Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H et al. (2005). Oncogene 24: 6323-6327.
14. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. (1998). Science 281: 1509-1512.
15. Herman JG, Baylin SB. (2003). N Engl J Med 349: 2042-2054.
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. (1996). Proc Natl Acad Sci USA 93: 9821-9826.
17. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G et al. (2004). Int J Oncol 25: 641-649.
18. Lai J, Flanagan J, Phillips WA, Chenevix-Trench G, Arnold J. (2003). Br J Cancer 88: 270-276.
19. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J et al. (2004). Oncogene 23: 6672-6676.
20. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y et al. (2000). Proc Natl Acad Sci USA 97: 4262-4266.
21. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. (2005). Cancer Res 65: 4218-4227.
22. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M et al. (1999). Proc Natl Acad Sci USA 96: 1603-1608.
23. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR et al. (2005). Cancer Res 65: 7081-7085.
24. Niederacher D, Picard F, van Roeyen C, An HX, Bender HG, Beckmann MW. (1997). Genes Chromosomes Cancer 18: 181-192.
25. Oshiro MM, Kim CJ, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Burr JA et al. (2005). Breast Cancer Res 7: R669-80.
26. Polakis P. (2000). Genes Dev 14: 1837-1851.
27. Remmele W, Stegner HE. (1987). Der Pathol 8: 138-140.
28. Seitz S, Rohde K, Bender E, Nothnagel A, Kolble K, Schlag PM et al. (1997). Oncogene 14: 741-743.
29. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E et al. (2004). Lab Invest 84: 465-478.
30. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP et al. (2002). Nat Genet 31: 141-149.
31. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD et al. (2004). Nat Genet 36: 417-422.
32. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao SW et al. (2004). Cancer Sci 95: 741-744.
33. Tetsu O, McCormick F. (1999). Nature 398: 422-426.
34. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. (1988). Cell 55: 619-625.
35. Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Jordan B et al. (1999). Oncogene 18: 1903-1910.
36. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F et al. (2001). Oncogene 20: 5810-5817.
37. Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP et al. (2000). J Biol Chem 275: 4374-4382.
38. Varga AE, Stourman NV, Zheng Q, Safina AF, Quan L, Li X et al. (2005). Oncogene 24: 5043-5052.
39. Waki T, Tamura G, Sato M, Motoyama T. (2003). Oncogene 22: 4128-4133.
40. Yokota T, Yoshimoto M, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y et al. (1999). Cancer 85: 447-452.